New drug combo shows promise for rare childhood muscle disease

NCT ID NCT05524311

First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This study tested whether baricitinib, a drug that calms the immune system, works better than standard treatment when combined with steroids for children aged 3 to 18 with newly diagnosed juvenile dermatomyositis, a rare disease causing muscle weakness and rash. Sixteen children took part over 24 weeks. The goal was to see if at least 20% improvement in muscle strength, daily function, and quality of life could be achieved safely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hopital Necker - Enfants malades : unité d'immuno-hématologie et rhumatologie

    Paris, France

  • Hôpital Brabois

    Nancy, France

  • Hôpital Femme Mère Enfant

    Bron, France

  • Hôpital Jeanne de Flandre

    Lille, France

  • Hôpital La Timone

    Marseille, France

  • Hôpital Necker - Enfants malades : service de dermatologie

    Paris, France

  • Hôpital Pellegrin

    Bordeaux, France

  • Hôpital Purpan

    Toulouse, France

  • Hôpital Robert Debré

    Paris, France

  • Hôpital Trousseau

    Paris, France

  • Hôpital Villeneuce

    Montpellier, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Hôpital du Kremlin-Bicêtre

    Paris, France

Conditions

Explore the condition pages connected to this study.